Together, let’s Be Lunacious and rewrite the story of global health.
Join the LunaVax Mission
Join us in closing the vaccine gap across Nigeria and Africa. We're tackling malaria, tuberculosis (TB), pneumococcal disease, Haemophilus influenzae type b (Hib), HPV, rotavirus, yellow fever, polio, measles, hepatitis B, and DTP (diphtheria, tetanus, and pertussis). Through local innovation and delivery, we welcome scientists, public health leaders, advocates, and bold thinkers to be part of the mission. Explore how you can get involved.
Vaccine Patches: Painless, Powerful, Needle-Free
We are advancing microneedle patches (MAPs), a painless, needle-free way to deliver vaccines in underserved areas. Our first pilot focuses on measles, with plans to expand into HPV, TB, and malaria, and a long-term goal of national integration and local production. Learn more about microneedle patches from Gavi.
Partner with LunaVax to advance vaccine access
LunaVax is advancing vaccine access in Africa through the LunaChain, a connected, multi-layered network for smarter delivery. From microneedle patches to biometrics, mobile units, and local manufacturing, we’re rethinking how vaccines reach families. We work with clinics, funders, and innovators to make immunization faster and more equitable. Join Us in Building the LunaChain.
MAP Vaccine Pilot Expansion: Lagos, Abuja, Adamawa & Anambra
Inside the Vial: Our Science
We are working to harness cutting-edge science to advance vial-based vaccines using mRNA, self-amplifying RNA (saRNA), protein subunit, viral vector, and DNA platforms. These safe, scalable technologies address Africa’s most urgent vaccine-preventable diseases and support Nigeria’s immunization goals for measles, TB, yellow fever, and rotavirus, where injectable formats remain essential. Explore our vaccine platforms.
Advocate for Vaccine Equity with Luna360
Join our global network driving awareness, policy change, and public support for equitable vaccine access. Use your voice to make vaccines a priority everywhere.
LunaVax, in collaboration with Harvard Medical School’s GCSRT program, is developing one of the world’s first Phase III study designs for microneedle vaccine patch (MAP) studies, with planned implementation across Lagos, Abuja, Adamawa, and Anambra. (Read the full story)
Stay updated on our latest breakthroughs! Explore our latest insights on vaccine innovation, partnerships, and funding.